Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from CMPS

Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins

Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to target a fourth-quarter New Drug Application filing for COMP360, its synthetic psilocybin treatment candidate for treatment-resistant depression, while preparing commercially for a potentially accelerated regulatory timel

MarketBeat · May 21

Compass Pathways Q1 Earnings Call Highlights

Compass Pathways (NASDAQ:CMPS) said it has begun a rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, and is preparing for a potential launch by the end of the year if the therapy is approved. On the company’s first-quar

MarketBeat · May 13

Trump Wants to Give Psychedelics Stocks a Boost. Can This Leading Company Deliver?

Trump signed an order to accelerate the regulatory progression of psychedelic therapies. Can Compass Pathways make use of it?

Barchart · Apr 28

From analysis to the latest developments in health,
read the most diverse news in one place.

Trump Sends Compass Pathways Stock Soaring as He Backs Psychedelics. Should You Buy CMPS Here?

Compass Pathways stock rallies as Trump’s new executive order aims at accelerating approval and research of psychedelic medicines. But is it too late to invest in CMPS shares already?

Barchart · Apr 20

Cathie Wood Bets $19 Million on 5 Beaten-Down Stocks

Cathie Woods’s ARK Invest deploys $19 million across five growth stocks in this uncertain market.

Barchart · Mar 10

This Psychedelic Drug Flopped on Trial Results. Should You Buy the Dip?

Compass Pathways took a 50% on June 23 hit after a lukewarm trial, but long-term bulls see upside in psychedelics.

Barchart · Jun 29, 2025

Compass Pathways Stock Is Plunging Today: What's Going On?

COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in the ongoing Phase 3 COMP005 trial, but results may have not met lofty investor expectations.

Benzinga · Jun 23, 2025

Read news from The Economist, FT, and more,
with one subscription

1 Biotech Stock Under $10 That Could Surge 420%

Down 84% from all-time highs, Compass Pathways is a beaten-down biotech stock that trades at a massive discount to consensus price target estimates in 2024.

Barchart · Jul 30, 2024

3 Shorted Stocks That Could Be Making a Comeback

With the onset of the earnings season, any positive development among heavily shorted stocks EVgo (EVGO), Amyris (AMRS), and COMPASS Pathways (CMPS) might trigger short squeezes to reward their backers. However, their fundamentals could catch up with them and prevent them from delivering sustained risk-adjusted returns once the dust settles.…

StockNews.com · Apr 10, 2023

COMPASS Pathways Shares Q3 2022 Financial Results, Business News & Term's Highlights

Psychedelics mental healthcare firm COMPASS Pathways (NASDAQ: CMPS) reported its financial outcomes for the third quarter ended 30 September 2022 and gave an update on its most recent pipeline and business developments.

Benzinga · Nov 4, 2022

Compass Pathways Will Lead Two Concurrent Phase 3 Trials On Psilocybin-Assisted Therapy For Depression

Psychedelics biotech company Compass Pathways (NASDAQ: CMPS) announced it will conduct two separate Phase 3 clinical trials to study psilocybin-assisted therapy on Treatment-Resistant Depression (TRD),

Benzinga · Oct 12, 2022

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.